Modulation of the immune response plays an important role in the natural history of renal cell carcinoma. Spontaneous regression of metastases has been well documented in a small percentage of patients after they undergo de-bulking nephrectomy without any additional systemic intervention. The only logical explanation for these observations is "resetting" of the balance between tumor and the host immune system that, having been overwhelmed by the tumor burden, is able to function better after tumor de-bulking. Attempts to modulate the activity of the immune system "on demand" have included the use of vaccines, cytokines/lymphokines, adoptive cell transfer, monoclonal antibodies and most recently manipulation of immune checkpoint inhibitors. Here we review the data for infusional interleukin-2 in the management of advanced renal cell carcinoma and its role in current clinical practice.
Introduction
Spontaneous regression of metastatic renal cell carcinoma has been reported in a small percentage of patients after de-bulking nephrectomy without any additional systemic intervention (1) (2) (3) . This is thought to be the result of "resetting" of the host immune system that had been overwhelmed by the tumor burden. Hence, immunotherapy has been the mainstay of treatment for advanced renal cell carcinoma until the introduction of targeted therapies. Interleukin 2 (IL-2) was approved by the USFDA in 1992 for the treatment of advanced renal cell carcinoma.
Interleukin-2
Demonstration that T lymphocytes could be grown in vitro, only in the presence of conditioned medium from phytohemagglutinin (PHA)-stimulated human blood lymphocytes (4) , led to the discovery of a T cell growth factor subsequently designated IL-2 (5, 6, 7) . T lymphocytes grown in IL-2 containing culture were shown to have the ability to kill tumor cells in vitro (8). IL-2 activated human peripheral blood lymphocytes showed lysis of natural killer-resistant fresh solid tumor cells -these were termed LAK cells (9).
IL-2 was deemed to be necessary and sufficient for T cell growth and activation.
In vivo animal studies demonstrated that adoptive immunotherapy with transfer of syngeneic LAK cells generated in vitro, using IL-2, could eliminate natural, killer-resistant, established pulmonary melanoma and sarcoma metastases (10, 11). IL-2 was shown to stimulate in vivo proliferation of adoptively transferred LAK cells (12), and systemic administration of high-dose IL-2 without adoptive T cell transfer was shown to cause regression of established pulmonary metastases and subcutaneous tumors, proving that LAK cells could be generated in vivo (13). The cDNA coding for IL-2 was cloned and was shown to consist of 153 amino acids with a molecular weight of 15,420 daltons (14) . Availability of IL-2 in large quantities made clinical trials possible. Rosenberg et al. reported their experience in 25 treatment-resistant patients with advanced cancer, who were treated with a combination of LAK cells and interleukin-2.
These included patients with malignant melanoma, colorectal cancer, sarcoma, renal cell carcinoma, non-small cell lung cancer and esophageal cancer. Eleven out of 25 patients had marked tumor regression; one patient with metastatic melanoma had a complete remission while 10 partial responses were observed, thus establishing proof of the principle that manipulation of the immune system using high-dose IL-2 could be performed safely and would induce significant clinically relevant responses (15) .
The discovery and availability of IL-2 for clinical use was pivotal in bringing an immunotherapeutic modality to the forefront (16).
Given that immunemediated regression had been observed in patients with renal cell carcinoma and the fact that renal cell carcinoma does not respond to chemotherapy, the earliest clinical investigations with IL-2, carried out at the NIH Surgery Branch, included renal cell carcinoma. A progress report on the treatment of 157 patients with advanced cancer, using LAK cells and IL-2 or highdose IL-2 alone, included 36 patients with renal cell carcinoma. An impressive 33% response rate was observed: 4/36 had a complete response and 8/36 had a partial response (≥ 50% decrease in sum of the products of the perpendicular diameters of all lesions). An additional 7/36 patients experienced a minor response (25 to 49% decrease in sum of the products). Most of the patients who had a complete response had lung metastases (17).
High-dose IL-2 in RCC
Further work at the NCI Surgery Branch reported their experience in 283 patients with metastatic melanoma or metastatic renal cell cancer treated from September 1985 through December 1992 with highdose bolus IL-2-this series included 149 patients with renal cell carcinoma. Patients received IL-2 at the dose of 720,000 international units per kilogram intravenously every 8 hours for a maximum of 15 doses per cycle: 2 cycles constituted a course of therapy. Patients who showed response or stable disease after the first course went on to receive additional therapy. An overall response of 20% (CR+PR) was observed in patients with renal cell carcinoma, 7% (n=10) achieved complete response, and 13% (n=20) had a partial response. With the exception of one complete responder who had liver metastases, all others had lung metastases or involvement of lymph nodes.
The responses were noted to be durable and ongoing at up to 76 months in the patients with a complete response, and 69 months in those with a partial response at the time of publication.
There were 3 (1.1%) treatment-related deaths; 2 due to myocardial infarction and one as a result of sepsis (18).
Some of the selected trials using high-dose IL-2 are summarised in Table 1 (21) .
In an effort to optimize IL-2 therapy, the renal cell "SELECT" trial was designed to assess if the patient population could be selectively enriched based on carbonic anhydrase IX overexpression within the tumor besides other factors. Of the 120 patients treated in this study, 96% had clear cell histology and 99% had nephrectomy. Patients received high-dose IL-2 at the dose of 600,000 international units per kilogram every 8 hours. The overall response rate was 29% (35/120): the response rate for clear cell histology was 30% (35/115). A complete response was observed in 7 patients, while 28 patients had a partial response. Although no correlation was noted with carbonic anhydrase IX expression, clear cell histology appeared to be important given the higher than historically observed response rates (22) .
High dose vs/or low dose IL-2
Despite the durable responses elicited by high-dose IL-2 that may translate into *CIV, intravenous; CR, complete response; ORR, overall response rate; OS, overall survival; PR, partial response; Sc, subcutaneous "cure" for some, its use is restricted to selected individuals with good organ function and performance status. Wider applicability is limited due to significant toxicity in the form of a brisk capillary leak syndrome that can result in multi-organ system compromise, albeit rapidly reversible but requiring intense monitoring and trained personnel in place. Efforts have therefore been made to study the efficacy of IL-2 at lower doses in the hope that treatment might be safer and easier to administer to a broader patient base. Some of the selected trials using low-dose IL-2 and comparing them to high-dose regimens are discussed ( Table 2 ).
In that vein, Negrier et al. reported 425 patients with metastatic renal cell carcinoma, randomized to receive IL-2 as a continuous intravenous infusion or interferon alpha 2a or the combination of both (23) . In the IL-2 monotherapy arm induction phase, drug was administered at the dose of 18 million international units per square meter of body surface area per day for 5 days repeated twice with a 6-day break.
In the maintenance phase, the same dose was repeated every 3 weeks. In the interferon monotherapy arm, drug was administered at the dose of 18 million international units subcutaneously 3 times a week for 10 weeks as induction and 13 JKCVHL 2014; 1(7):74-83 http://jkcvhl.com 78 additional weeks as maintenance. In the combination arm, IL-2 was administered at full dose (as above) but interferon alpha 2a was administered at the dose of 6 million international units 3 times a week during IL-2 dosing. The response rates were 6.5% for low dose IL-2 monotherapy, 7.5% for interferon alpha 2a monotherapy and 18.6% for the combination. There was no significant difference in overall survival, and toxicity was greater in the IL-2 containing arms.
The Surgery Branch at the NCI conducted a 3 arm randomized study comparing highdose IL-2 to two different low-dose IL-2 regimens (24). A total of 156 patients were assigned to the high-dose arm and received IL-2 at the dose of 720,000 international units per kilogram IV bolus every 8 hours.150 patients received low-dose IL-2 at the dose of 72,000 international units per kilograms IV bolus every 8 hours, while 94 patients in the third arm received daily subcutaneous low-dose IL-2. The response rate in the high-dose arm was 21%, 13% in the low-dose intravenous arm, and 10% in the daily subcutaneous. There were no treatment-related deaths. Toxicities, especially hypotension, were less frequent in the low-dose arms. Durable responses were noted in all arms: 8/11 patients who achieved a complete response in the highdose arm were noted to have an ongoing response at 9.3 years. Three of the 6 patients who achieved complete response in the low-dose intravenous arm were noted to have ongoing response at 10.1 years and one complete response in the subcutaneous low-dose arm had an ongoing response past 78 months at the time of analysis.
The Cytokine Working Group further conducted a randomized phase III study to compare high-dose IL-2 with the combination of low-dose subcutaneous -IL-2 and interferon (25) . In this study 91 patients received outpatient subcutaneous IL-2 at a loading dose of 5 million units per body meter squared every 8 hours for 3 doses on day 1 followed by 5 million units per meter squared on days 2, 3, 4 and 5 during the first week and then 5 million units per body meter squared for 5 days every week for 3 weeks. In addition these patients received interferon at the dose of 5 million units per meter squared thrice weekly for 4 weeks. A total of 95 patients were treated on the high-dose intravenous IL-2 arm and received 600,000 units per kilogram IV bolus every 8 hours for a maximum of 14 doses. An overall response of 23.2% (22/95) was observed in the highdose intravenous IL-2 arm compared to 9.9% (9/91) in the low-dose subcutaneous IL-2 plus interferon arm. Eight patients achieved a complete response in the highdose intravenous IL-2 arm; this response was durable in 7/8 patients at 3 years. Three of 9 responding patients achieved a complete response in the low-dose subcutaneous IL-2 plus interferon arm, but all of them had recurrence of disease within 3 years.
The French immunotherapy intergroup conducted a randomized trial to compare low dose subcutaneous IL-2, interferon alpha 2a, the combination of the 2 cytokines and medroxyprogesterone in 492 patients with metastatic renal cell carcinoma of intermediate prognosis (26) . Intermediate prognosis was defined by requiring a Karnofsky score of ≥80% if metastases in more than one organ; Karnofsky score of 80% if metastases in one organ; normal blood, liver and renal function. Patients with prior treatment, evidence of brain metastasis, uncontrolled cardiac issues, active infections or who were on corticosteroids were excluded. Subcutaneous IL-2 was administered at the dose of 9 million international units every day to 125 patients. 122 patients received interferon alpha 2a at the dose of 9 million international units 3 times a week. 122 patients received both interferon and IL-2 at the above doses, and 123 patients received medroxyprogesterone acetate at the dose of 200 mg every day. The response rate was 3.3% in the IL-2 arm, 3.5% in the interferon arm, 10.9% in the cytokine combination arm, and 1.7% in the medroxyprogesterone arm. No differences were noted in the progression-free survival or overall survival amongst all the arms.
High
Dose IL-2 -Contemporary Experience: "PROCLAIM"
Based on the relatively poor results associated with low-dose IL-2 high-dose IL-2 has generally come to be accepted as the standard of care for properly selected patients. Since the early trials that led to the approval of high dose IL-2, centers of excellence have developed treatment schema that can greatly reduce toxicities. Mitigation strategies and guidelines to safely administer high-dose interleukin-2 have since been developed and used effectively (27) The goals of the PROCLAIM registry are to: (i), provide information regarding IL-2 and its prospective use; (ii), compare the difference in administration approaches for their respective effect on outcomes; (iii), validate efficacy of high-dose IL-2 on response and survival in the treatment of malignant diseases; (iv), identify patients and site-specific prognostic factors and (v), study and potentially guide the emergence of new therapeutic options in the immunological armamentarium. Despite the compelling high dose IL-2 data, many oncologists now employ targeted therapy with suppression of the VEGF or mTOR pathways as initial therapy in patients with advanced renal cell carcinoma.
Retrospective reports with small numbers of patients treated with high-dose IL-2 after treatment with targeted therapy suggest higher than expected cardiovascular toxicity (some quite profound including cerebral vasculitis) if patients have previously received VEGF-targeted therapy (32) . The PROCLAIM registry was queried to address the question of optimal sequencing of IL-2 therapy with targeted therapy. Observations from the retrospective data cohort presented by Morse et al. (33) showed the median overall survival for patients (n=82) who received high-dose IL-2 as initial systemic treatment to be 61.8 months compared to 48 months for those (n=15) who had received targeted therapy prior to high-dose (IL-2).
While not conclusive, this observation suggests superior results in patients treated with high dose IL2 as first line therapy.
Discussion
Immunotherapy with high-dose IL-2 had been the mainstay of systemic treatment for advanced renal cell carcinoma until the development of agents inhibiting the VEGF and mTOR pathways.
VEGF TKIs (sunitinib, pazopanib, axitinib, sorafenib), mTOR inhibitors (temsirolimus, everolimus) and the combination of bevacizumab plus interferon have been approved for treatment of patients with metastatic renal cell carcinoma by the US FDA (34). Availability of these agents has had an impact on the natural history of the disease with prolongation of median survival to 22 months (35). Durable long-term responses observed with immunotherapy have, however, rarely been reported with these agents.
Given that treatment with high-dose IL-2 is not applicable for many patients with advanced renal cell carcinoma, new Hammers et al. presented data from a phase I study with the combination of nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma. Ipilimumab is a fully humanized IgG1 antibody that binds to the immune inhibitory checkpoint CTLA-4. Binding of anti-CTLA-4 antibody to CTLA-4 expressed on the surface of activated T cells prevents the T cell from switching off (39) . Ipilimumab has been approved for treatment of patients' metastatic melanoma (34). Almost 80% of the patients in the study had received at least one prior line of treatment prior to receiving the combination. The overall response rate for nivolumab at 3mg/kg and ipilimumab 1 mg/kg was 43%: 78% of the responders had ongoing responses at the time of analysis (24 weeks). The combination of the two drugs was tolerated well with treatment-related 'select' adverse events (defined as above) observed in less than 5% of the patients (40). Amin et al. reported data for the phase I study with the combination of nivolumab with either sunitinib or pazopanib in patients with metastatic renal cell carcinoma. The overall response rate was 52% and 45% in the sunitinib and pazopanib combination arms respectively. While there were no treatment-related deaths, 82% in the sunitinib arm and 70% in the pazopanib arm experienced grade 3-4 treatmentrelated toxicities (41) . These immunotherapeutic approaches hold great promise but mature data addressing the durability of these responses is awaited. 
Conclusion

